Taking place February 18-20, 2027, in New York City, the world-renowned integrative and functional medicine leaders will guide the agenda for the 22nd Annual Symposium NEEDHAM, Mass., Oct. 13, 2026 /PRNewswire/ — The Integrative Healthcare Symposium (IHS) today announced David… … […]
COVID-19 accelerated efforts to develop faster, more efficient ways of manufacturing high-quality RNA sequences.
The post How COVID, Characterization, and Commerce Are Driving an RNA Revolution appeared first on GEN – Genetic Engineering and Biotechnology News. … […]
Zealand Pharma is a biotechnology company transforming metabolic health so millions of people can live without limits. With the opening of its new research hub at 35 CambridgePark Drive, Zealand Pharma is building a bridge between the science it has nurtured in Copenhagen for three decades and the extraordinary talent,… … […]
CAMBRIDGE, Mass.–(BUSINESS WIRE)– #ArtificialIntelligence–Quantori has been named a Major Contender in Everest Group’s Pharmaceutical R&D IT Services PEAK Matrix® Assessment 2026 … […]
New research from HomeExchange and Ipsos BVA finds nearly two-thirds of Americans trust others less than they did a decade ago and identifies what it could take to reverse the trend. CAMBRIDGE, Mass., Oct. 13, 2026 /PRNewswire/ — The United States stands out in the inaugural HomeExchange… … […]
WILMINGTON, Mass.–(BUSINESS WIRE)—- $CRL #CDMO–Charles River Laboratories International, Inc. (NYSE: CRL) and Magellan Stem Cells, a private Australian biotech and cell-therapy firm, announce their collaboration to support Magellan in the development and clinical advancement of its proprietary stem cell-based therapies and regenerative medicine solutions. The partnership will leverage Charles River’s… … […]
The German pharmaceutical giant is consolidating its investment leadership at a new Cambridge office. … […]
A new approach can program these cells inside the body and shows promise against diseases caused by dysfunctional T cells, including lymphoma and autoimmune hepatitis. … […]
Associate Professor David Des Marais studies how plants interact with their surroundings and adapt over time. … […]
Caribou has halted trials of vispacabtagene regedleucel (vispa-cel, formerly CB-010) a treatment for relapsed or refractory B cell non-Hodgkin lymphoma; and of CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of patients with r/r multiple myeloma. The post StockWatch: Caribou Plunges as It Pursues Strategic Alternatives appeared… … […]
Copyright © 2026 Biotech Networks, LLC
